ABBV · News · 20260921N

Licensing / Collaboration Deals

AbbVie Inc. · 2026-09-21 · Importance 31 · Surprise 42

AbbVie and Iambic entered a multi-year collaboration on September 21, 2026, focused on AI-driven small-molecule drug discovery. The collaboration covers AbbVie’s immunology, neuroscience, and oncology therapeutic areas. Iambic will provide its molecular superintelligence platform, including Enchant and NeuralPLexer, while AbbVie contributes therapeutic expertise. The parties expect the collaboration to shorten drug-discovery timelines and support development of new medicines.

Key facts

• AbbVie and Iambic announced a multi-year collaboration to use Iambic's AI platform for accelerating small molecule drug discovery in immunology, neuroscience, and oncology. source
• The collaboration will leverage Iambic's molecular superintelligence platform, which includes technologies named Enchant and NeuralPLexer, alongside AbbVie's therapeutic expertise. source
• Representative Pete Sessions sold between $30,002 and $100,000 worth of AbbVie stock on September 14, 2026. source
• A congressional trade report shows Representative Pete Sessions sold AbbVie shares on September 14, 2026 involving a value between $15,001 and $50,000 held in an ET IRA. source
• The collaboration is expected to reduce drug discovery timelines and lead to the development of better medicines for patients. source